German medics say they are not under pressure to switch patients on Remicade to infliximab biosimilars
The majority of German patients receiving an infliximab biosimilar were biologic-naive and would have received Merck & Co’s Remicade (infliximab) or another biologic if they had not received a biosimilar, according to surveyed German rheumatologists and gastroenterologists.
According to a new report from Decision Resources, at three months post launch of infliximab biosimilars (Inflectra, from Hospira and Remsima, from CellTrion), less than one-quarter of respondents had experienced any pressure from health care authorities to switch patients currently treated with Remicade to receive an infliximab biosimilar.
Other key findings from the biosimilars report, titled LaunchTrends: Inflectra/Remsima (Germany), are:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze